Search Results - "Margossian, Astrid L."

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing by Gray, Heidi J., Chatterjee, Payel, Rosati, Rachele, Appleyard, Lauren R., Durenberger, Grace J., Diaz, Robert L., Swan, Hallie A., Peretti, Danielle, Pollastro, Maddy, Ainge, Trevor, Kapeli, Katannya, Pereira, Shalini, Margossian, Astrid L., Banda, Kalyan, Goff, Barbara A., Swisher, Elizabeth M., Bernard, Brady, Kemp, Christopher J., Grandori, Carla

“…Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We…”
Get full text

DNA methylation as a biomarker in breast cancer by Martens, John Wm, Margossian, Astrid L, Schmitt, Manfred, Foekens, John, Harbeck, Nadia

“…In cancer, epigenetic changes such as covalent addition of methyl groups to the genomic DNA itself are more prominent than genetic changes…”
Get more information

Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients by PATHIRAJA, Thushangi N, SHETTY, Priya B, JELINEK, Jaroslav, RONG HE, HARTMAIER, Ryan, MARGOSSIAN, Astrid L, HILSENBECK, Susan G, ISSA, Jean-Pierre J, OESTERREICH, Steffi

“…ERα and PR levels are critical determinants for breast cancer prognosis and response to endocrine therapy. Although PR is known to be silenced by methylation…”
Get full text

Abstract P6-08-30: BRCA 1/2 tests and beyond, across a breast center population: 10 years analysis and review of mutations and variants of uncertain significance by Margossian, Astrid L, Nicastro, Ana I, Colica, Maria V

“…Abstract Introduction: In our “Breast Center Buenos Aires” population of 3854 patients, accessibility of BRCA1/2 testing started at 2009 and dramatically…”
Get full text